Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pfizer Inc, Johnson & Johnson Alzheimer's Drug Fails One Of Four Big Trials- Reuters


Monday, 23 Jul 2012 08:00pm EDT 

Reuters reported that Pfizer Inc experimental Alzheimer's disease treatment failed to prove effective in one of four high-stakes late-stage trials in patients with mild to moderate forms of the memory-robbing disease. The trial involved people who carry a variation of a gene called ApoE4 that makes them far more likely to develop Alzheimer's disease. Pfizer said it and its partner Johnson & Johnson would continue with three other late-stage trials of their medicine, called bapineuzumab, based upon a review by independent safety monitors. The drug failed to improve cognitive and life function, the primary goals of the trial, compared with patients taking placebos. Alzheimer's is the a common form of dementia and the sixth leading cause of death in the United States. 

Company Quote

98.75
-0.45 -0.45%
16 Apr 2014